and Human Papillomavirus (HPV) DNA With Reflex to HPV E6/E7 (QuantaSURE®) Visit the online Test Menu at www.LabCorp.com for full test information, including CPT codes and specimen collection requirements. HPV E6/E7 QuantaSURE® • Correlation to disease with a PPV of 78% vs DNA testing PPV of 43% in cells for CIN2+4 Of the 1,896 women with normal cytology and HPV mRNA test (intervention group), 49 women (2.6%) had a positive test. The risks of CIN3+ among women with either a positive or negative HPV mRNA test were 28.6% (14/49) and 0.8% (14/1847). None of the women in the intervention group developed cervical cancer during follow-up. High risk HPV testing for these patients increases the efficiency of the screening programme. A British study has demonstrated that only 0,2% of women with negative HPV and cytology post treatment had CIN2 at 5 years and only 2,4% of women with negative HPV test and inadequate cytology or ASC-US post treatment had CIN2 at 5 years. 99.7% of high risk HPV is attributable to developing cervical cancer. The discovery that high-risk HPV as a cause of virtually all cervical carcinoma has prompted international interest in the use of HPV DNA testing in cervical cancer screening programmes. High-risk HPV testing will be incorporated in cervical cancer screening from 2019. This was done using: (1) one of two DNA-based assays (HC2 or CB) and (2) the two DNA-based (HC2 or CB) versus an RNA-based (AHPV) assays, by investigating the positive and negative testing rates as well as the ten-year risk of CIN2+ and CIN3+ among participants in FOCAL-DECADE who had a baseline negative HPV test using one of the three assays. Comparing HPV test methods between HC2 and highly sensitive PCR techniques showed that 14 (10.2%) out of 136 women with cervical cancer in Spain were HPV negative based on HC2 test, whereas only 8 (5.8%) cases were confirmed to be truly HPV-negative based on PCR test . Another study showed consistent results . A PCR based virus testing has been High volume sample-throughput testing with the digene HC2 HPV DNA Test can be performed utilizing the Rapid Capture® System (RCS). This instrument processes up to 352 specimens in eight hours. To enable high volume sample-throughput testing, all the procedural steps of the assay are performed by the At any given time, about 42 million people are infected with HPV and may not even know it. HPV is the cause of most cancers of the cervix (and vagina). But most HPV infections clear on their own or become undetectable, and most infections never lead to disease (such as genital warts or changing cervical cells found by a Pap test). CVqF.